M.D., MS, Chief Scientific Officer, Personalis
Biography
As Chief Scientific Officer, Dr. Chen leads research, development, and clinical efforts at Personalis. He leads a team of bioinformaticians, engineers, scientists, and clinicians developing genomics-based precision medicine solutions in cancer and immuno-oncology. A physician scientist, Dr. Chen has extensive industry experience in immuno-oncology, bioinformatics, systems biology, translational genomics, and product development. Dr. Chen has co-founded and served on the board of several companies, including Ingenuity Systems which pioneered systems biology approaches to genomic data analysis for scientific discovery and data interpretation. Dr. Chen has also served on the clinical faculty at Stanford University School of Medicine where he led process and technology innovation for improved health care delivery. Dr. Chen received a BS in Computer Science, MS in Biomedical Informatics, and a MD from Stanford University and Medical School. He completed his Chief Residency and Dermatology Specialty Training at Stanford and is board certified.
Enabling Integrative, Composite Biomarkers For Cancer Diagnostics And Therapy
Session Abstract – PMWC 2020 Silicon Valley
Track 6 - January 23 2.00 P.M.-3.45 P.M.,Track 6 - January 24 10.30 A.M.-4.30 P.M.
The PMWC 2020 Emerging Therapeutics Showcase will provide a 15-minute time slot for selected companies and researchers in the CRISPR, Cell and Gene Therapy fields. Major advancements in safer cell- and gene-level editing technologies are bringing us closer toward cures for life-threatening disorders, from cancer to HIV to Huntington’s disease. Cell therapy, in which cellular material such as T cells capable of fighting cancer cells, is injected into a patient, has been demonstrated safe and effective. The popular new CRISPR tool that has been used to edit the genetic code of nearly any organism will have an enormous impact on human health. More than a dozen clinical trials employing CRISPR on human cells are already underway.
